International Journal of Pharmaceutical Drug Design (IJPDD)
Website: https://ijpdd.org/
ISSN: 2584-2897
Vol. 3, Issue 1, January-June, 2026
Page No.: 98-104

Review

Smart Nanocarriers in Targeted Cancer Therapy: Current Progress and Future Directions

Padole Jyoti R.*, Mahajan Prasad L., Lute Sanchita S., Ighare Sunil G.

Dnyansadhana College of Pharmacy, Dharmapuri Parbhani

Corresponding Author:
Padole Jyoti R.

Email:
jyotirpadole@gmail.com

DOI: *10.62896/ijpdd.3.1.13*

Conflict of interest: *NIL*

Article History
Received: 12/12/2025
Accepted: 24/03/2026
Published: 10/04/2026

Abstract:
Cancer continues to be a major global health challenge due to complications such as metastasis, multidrug resistance, and ineffective site-specific drug delivery. Traditional treatment modalities, including chemotherapy and radiotherapy, often lack selectivity and result in significant damage to healthy tissues. Nanomedicine has emerged as a promising strategy to overcome these limitations by enhancing both diagnosis and treatment. Various nanocarriers—such as liposomes, micelles, dendrimers, silica nanoparticles, gold nanoparticles, iron oxide nanoparticles, carbon nanotubes, and quantum dots—offer advantages including nanoscale size, high drug-loading efficiency, and tumor-targeting capability. Both naturally derived and synthetic nanocarriers are under extensive investigation. Natural systems like exosomes provide superior biocompatibility, while synthetic carriers allow controlled drug release and structural adaptability. Advanced systems such as biomimetic nanoparticles improve immune evasion and prolong circulation time. Additionally, carrier-free nanodrugs provide higher drug content with reduced toxicity. Overall, smart nanocarriers significantly enhance therapeutic outcomes while minimizing adverse effects, highlighting their importance in modern cancer therapy.

Keywords: Cancer; Nanomedicine; Smart nanocarriers; Targeted delivery; Stimuli-responsive systems; Theranostics

Introduction

Cancer remains one of the leading causes of mortality worldwide, with conventional therapies often limited by poor selectivity and severe side effects [1]. Chemotherapy, although effective in killing cancer cells, also damages normal cells, leading to complications such as immunosuppression, organ toxicity, and hair loss.

Another major challenge is drug resistance and tumor heterogeneity, which complicate treatment outcomes [10]. To address these issues, advanced drug delivery systems such as smart nanocarriers have been developed. These nanoscale systems enable precise delivery of therapeutic agents directly to tumor tissues, thereby improving efficacy and reducing systemic toxicity [2].

Smart nanocarriers are capable of responding to internal (pH, enzymes) or external (temperature, light) stimuli, allowing controlled drug release at the target site. Additionally, they support theranostic applications by combining drug delivery with imaging for real-time monitoring of cancer progression [3].

Literature Survey

Author (Year)	Nanocarrier/System	Key Contribution	Ref
Peer et al. (2007)	Nanocarriers	Introduced nanocarriers as targeted therapeutic platforms	[2]

Author (Year)	Nanocarrier/System	Key Contribution	Ref
Kamaly et al. (2016)	Polymeric nanoparticles	Mechanisms of controlled drug release	[3]
Owen et al. (2012)	Polymeric micelles	Stability issues and optimization strategies	[4]
Akbarzadeh et al. (2013)	Liposomes	Classification and biomedical applications	[5]
Singh et al. (2018)	Gold nanoparticles	Role in cancer diagnostics and therapy	[6]
Zrazhevskiy et al. (2010)	Quantum dots	Multifunctional imaging and drug delivery	[7]
Liu et al. (2011)	Carbon nanotubes	Drug delivery and cancer therapy applications	[8]
Hossen et al. (2019)	Smart nanocarriers	Targeted therapy and toxicity evaluation	[20]

Aim and Objectives

Aim:

To analyze the potential of smart nanocarriers in improving targeted cancer therapy.

Objectives:

- To describe different types of nanocarriers and their properties
- To understand targeting mechanisms and drug release strategies
- To evaluate advantages and limitations of nanocarrier systems
- To explore emerging trends and future prospects in nanomedicine

Results and Discussion

Smart nanocarriers represent a major advancement in targeted cancer therapy due to their ability to improve drug localization, control release kinetics, and minimize systemic toxicity. Their effectiveness depends on multiple interconnected factors including targeting mechanisms, carrier design, biological interactions, and therapeutic performance.

1. Targeting Mechanisms and Tumor Accumulation





Nanocarriers utilize two principal targeting strategies:

Passive Targeting (EPR Effect)

Tumor tissues possess abnormal vasculature with large fenestrations and impaired lymphatic drainage. This allows nanoparticles (typically 10–200 nm) to accumulate preferentially in tumor regions, a phenomenon known as the **Enhanced Permeability and Retention (EPR) effect** [2]. Liposomes and polymeric nanoparticles effectively exploit this mechanism.

Active Targeting

Active targeting enhances specificity by functionalizing nanocarrier surfaces with ligands such as antibodies, peptides, or folic acid. These ligands bind selectively to overexpressed receptors on cancer cells, facilitating receptor-mediated uptake [2].

Discussion Insight:

While passive targeting ensures accumulation, active targeting improves cellular internalization and therapeutic precision. However, heterogeneity in receptor expression across tumors can affect targeting efficiency.

2. Cellular Uptake and Intracellular Trafficking

International Journal of Pharmaceutical Drug Design (IJPDD)
Website: https://ijpdd.org/
ISSN: 2584-2897
Vol. 3, Issue 1, January-June, 2026
Page No.: 98-104



After reaching the tumor microenvironment, nanocarriers interact with cancer cells and enter via **endocytosis mechanisms**, primarily receptor-mediated endocytosis.

Once internalized, nanoparticles are transported through intracellular compartments such as endosomes and lysosomes. Smart nanocarriers are engineered to escape lysosomal degradation and release drugs into the cytoplasm.

Discussion Insight:

Efficient intracellular trafficking is critical for therapeutic success. Poor endosomal escape can lead to drug degradation and reduced efficacy.

3. Stimuli-Responsive Drug Release





Smart nanocarriers are designed to release drugs in response to **specific internal or external stimuli**:

- **pH-sensitive systems:** Release drugs in acidic tumor environments
- **Enzyme-responsive systems:** Activated by tumor-specific enzymes
- **Thermo/light/magnetic-sensitive systems:** Triggered externally

These systems ensure **site-specific drug release**, reducing premature leakage and systemic toxicity [3,14].

Discussion Insight:

Stimuli-responsive systems significantly enhance therapeutic precision, but designing multi-responsive carriers remains complex.

4. Types of Nanocarriers and Functional Roles

(a) Liposomes and Micelles



- **Liposomes:** Biocompatible vesicles capable of carrying both hydrophilic and hydrophobic drugs [5]
- **Micelles:** Amphiphilic systems improving solubility of poorly water-soluble drugs [4]

Discussion: Widely used due to safety and clinical approval (e.g., liposomal doxorubicin), but stability issues persist.



(b) Dendrimers and Carbon Nanotubes









- **Dendrimers:** Highly branched polymers with high drug-loading capacity and controlled release [29]
- **Carbon nanotubes (CNTs):** Enable delivery of drugs and genetic material across biological barriers [8,9]

Discussion: These carriers offer precision and versatility but raise concerns regarding toxicity and long-term safety.

(c) Magnetic Nanoparticles and Quantum Dots



- **SPIONs:** Allow external magnetic field-guided targeting and imaging [24]
- **Quantum dots:** Provide simultaneous imaging and drug delivery (theranostics) [7]

Discussion: These systems enable real-time monitoring but require careful toxicity evaluation due to inorganic composition.

5. Therapeutic Advantages

Smart nanocarriers provide several clinically relevant benefits:

- **Enhanced targeting efficiency** via EPR and ligand-based mechanisms
- **Reduced systemic toxicity** by limiting drug exposure to healthy tissues
- **Improved bioavailability** of poorly soluble drugs
- **Controlled and sustained drug release**
- **Overcoming multidrug resistance (MDR)** by bypassing efflux pumps

These advantages collectively improve therapeutic outcomes and patient compliance [16].

6. Limitations and Challenges

Despite promising results, several challenges hinder clinical translation:

- **Complex manufacturing and high cost**
- **Stability issues during storage**
- **Potential toxicity of inorganic nanoparticles**
- **Non-specific accumulation in liver and spleen (RES uptake)**
- **Tumor heterogeneity affecting targeting efficiency**
- **Regulatory and scalability challenges** [30]

Discussion Insight:

Bridging the gap between laboratory success and clinical application requires improved reproducibility, safety profiling, and cost-effective production.

7. Overall Discussion Perspective

Smart nanocarriers integrate multiple functionalities—targeting, controlled release, and imaging—into a single platform. This multifunctionality supports **precision oncology**, enabling tailored therapies for individual patients.

However, future research must focus on:

- Enhancing biocompatibility
- Improving tumor penetration
- Reducing off-target effects
- Achieving large-scale clinical translation

Conclusion of Discussion Section

The results clearly demonstrate that smart nanocarriers significantly improve cancer treatment outcomes compared to conventional therapies. While challenges remain, continued advancements in nanotechnology and biomedical engineering are expected to overcome these limitations and establish nanocarrier-based systems as a cornerstone of modern cancer therapy [16,30].

Limitations

- Complex and expensive manufacturing processes
- Stability and storage issues
- Potential toxicity of inorganic nanoparticles
- Limited clinical translation

- Challenges in biodistribution and clearance
- Regulatory and scalability concerns [30]

Smart nanocarriers also facilitate **theranostic applications**, combining therapy with diagnostic imaging, thereby improving precision medicine [16].

Future Scope

Future advancements in nanocarrier-based cancer therapy include:

- Development of personalized nanomedicine based on genetic and molecular profiling
- Integration with gene therapy and immunotherapy
- Design of multifunctional theranostic systems
- Application of artificial intelligence for optimized nanocarrier design
- Engineering biodegradable and biocompatible materials
- Overcoming biological barriers such as the blood–brain barrier

These innovations are expected to significantly improve treatment outcomes and enable precision oncology.

Conclusion

Smart nanocarriers have emerged as a highly promising approach for targeted cancer therapy by improving drug delivery accuracy and minimizing adverse effects. Their ability to integrate targeting mechanisms with controlled release and diagnostic capabilities makes them powerful tools in modern oncology. Despite existing challenges such as toxicity, cost, and regulatory hurdles, continuous advancements in nanotechnology and biomedical research are expected to accelerate their clinical translation. Ultimately, smart nanocarriers hold the potential to revolutionize cancer treatment by enabling safer, more effective, and personalized therapeutic strategies.

References

1. Bray F, et al. Global cancer statistics 2018. CA Cancer J Clin. 2018;68:394–424.
2. Peer D, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751–760.
3. Kamaly N, et al. Controlled-release polymeric nanoparticles. Chem Rev. 2016;116:2602–2663.
4. Owen SC, et al. Polymeric micelle stability. Nano Today. 2012;7:53–65.
5. Akbarzadeh A, et al. Liposome applications. Nanoscale Res Lett. 2013;8:102.
6. Singh P, et al. Gold nanoparticles in cancer therapy. Int J Mol Sci. 2018;19:1979.
7. Zrazhevskiy P, et al. Quantum dots in bioimaging. Chem Soc Rev. 2010;39:4326–4354.
8. Liu Z, et al. Carbon nanotubes in cancer therapy. Mater Today. 2011;14:316–323.
9. Eatemadi A, et al. Carbon nanotubes applications. Nanoscale Res Lett. 2014;9:393.
10. Siegel RL, et al. Cancer statistics 2015. CA Cancer J Clin. 2015;65:5–29.
11. Torchilin VP. Smart nanocarriers. Nat Rev Drug Discov. 2014;13:813–827.
12. Kumar R, Kulkarni A. Smart nanocarriers review. Mater Today Proc. 2021;47:2865–2872.
13. Batrakova EV, Kabanov AV. Polymeric nanocarriers. J Control Release. 2008;130:98–106.
14. Wang Y, et al. Stimuli-responsive nanocarriers. Nano Today. 2018;20:77–95.
15. Zhang X, et al. Smart nanocarriers progress. Adv Mater. 2020;32:1901081.
16. Sahoo SK, Labhasetwar V. Nanotech in cancer therapy. Drug Discov Today. 2003;8:1112–1120.
17. Pérez-Herrero E, Fernández-Medarde A. Targeted nanocarriers. Eur J Pharm Biopharm. 2015;93:52–79.
18. Huda S, et al. Smart nanocarriers strategy. J Drug Deliv Sci Technol. 2020;60:102018.
19. Hossen S, et al. Nanocarrier-based drug delivery. J Adv Res. 2019;15:1–18.
20. Hanahan D, Weinberg RA. Hallmarks of cancer. Cell. 2011;144:646–674.
21. Kumari P, et al. Nanocarriers in cancer. J Drug Target. 2016;24:179–191.
22. Chomoucka J, et al. Magnetic nanoparticles. Pharmacol Res. 2010;62:144–149.

23. Wang Y, et al. Mesoporous silica nanoparticles. Nanomedicine. 2015;11:313–327.
24. Son KH, et al. Carbon nanotubes in therapy. Int J Nanomed. 2016;11:5163.
25. Nanjwade BK, et al. Dendrimers review. Eur J Pharm Sci. 2009.
26. Wang X, et al. Smart drug delivery systems. Biosci Rep. 2022.

*****